Organisation paid for research Program year 2025 Source: CMS Open Payments

Anderson Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,534,210

322 payments

Through program year 2025, Anderson Clinical Research is reported as receiving $1,534,210 in research payments, across 322 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $501,457 34
2024 Research $3,821 2
2023 Research $16,658 5
2022 Research $20,303 8
2021 Research $60,801 35
2020 Research $111,781 56
2019 Research $819,389 182

Breakdown

Who paid Research payments · program years 2019–2025
  1. Axsome Therapeutics, Inc. $433,016 23 payments
  2. Alkermes, Inc. $347,378 171 payments
  3. Biogen, Inc. $258,724 2 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $110,999 4 payments
  5. Allergan Inc. $81,604 14 payments
  6. Genentech, Inc. $75,349 10 payments
  7. Eli Lilly and Company $67,444 32 payments
  8. Eisai Inc. $48,914 26 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $41,454 3 payments
  10. E.R. Squibb & Sons, L.L.C. $40,377 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms $433,016 23 payments
  2. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $258,724 2 payments
  3. A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder $166,089 65 payments
  4. Prodromal to Mild Ad $75,349 10 payments
  5. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $71,375 1 payment
  6. Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 $64,768 44 payments
  7. A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Rapastinel As Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder $59,624 9 payments
  8. A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder $48,914 26 payments
  9. A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder $41,658 18 payments
  10. PoCC dose finding in Mild to Moderate AD $41,454 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record